​

Exciva is currently developing an investigational product (EXV-802) for potential treatment for agitation in people with Alzheimer’s Disease. Exciva understands that there may be people who are interested in access to EXV-802 outside of a clinical trial. At this stage of development, the only way to gain access to EXV-802 is by participating in a clinical study.

 

Exciva is committed to supporting people with Alzheimer’s Disease suffering from agitation and their families by aiming for regulatory approval to provide access to as many people as possible who are most likely to benefit. As Exciva is collecting more clinical data on the safety and efficacy of EXV-802, the company will carefully reconsider the Expanded Access Policy as needed to ensure that it will be aligned with the best interests of such individuals. 

 

Should you have any questions regarding Exciva’s Expanded Access Policy, please contact studies@exciva.com. Please do not send us any personal health information.